StreetInsider.com News Articles

Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea

Wed, 19 Aug 2026 08:00:00 -0400

SAN CLEMENTE, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthetics company advancing non-invasive technologies for skin and body, today announced that it has surpassed one million Sofwave® treatments worldwide. The milestone treatment was performed in South Korea, one of the world’s most sophisticated and competitive medical-aesthetics markets.

The milestone follows sustained, consistent growth in treatment volume. Sofwave reported more than 770,000 treatments at the end of 2025, more than 865,000 as of March 31, 2026, and more than 975,000 as of June 30, 2026.

Reaching one million treatments

Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea

Wed, 19 Aug 2026 08:00:00 -0400

Reaching one million treatments

Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea

Wed, 19 Aug 2026 08:00:00 -0400

Reaching one million treatments

Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea

Wed, 19 Aug 2026 08:00:00 -0400

Reaching one million treatments

Sofwave Medical Reports Second Quarter and First Half 2026 Financial Results and Business Highlights

Tue, 04 Aug 2026 08:30:00 -0400

Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5%
Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growth
First half revenue of $54.4M, +44% year-over-year growth; IFRS gross margin of 75.8%
Second quarter IFRS and non-IFRS net income of $2.5M and $3.0M (or $3.8M exc. one-time expenses), versus IFRS and non-IFRS net income of $1.5M and $2.2M in the prior year period
Generated $3.6M in cash in the second quarter
Approximately 3,100 Sofwave systems sold to date and more than 975,000 Sofwave treatments administered since commercialization

Sofwave Medical Reports Second Quarter and First Half 2026 Financial Results and Business Highlights

Tue, 04 Aug 2026 08:30:00 -0400

Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5%
Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growth
First half revenue of $54.4M, +44% year-over-year growth; IFRS gross margin of 75.8%
Second quarter IFRS and non-IFRS net income of $2.5M and $3.0M (or $3.8M exc. one-time expenses), versus IFRS and non-IFRS net income of $1.5M and $2.2M in the prior year period
Generated $3.6M in cash in the second quarter
Approximately 3,100 Sofwave systems sold to date and more than 975,000 Sofwave treatments administered since commercialization

Sofwave Medical Reports Second Quarter and First Half 2026 Financial Results and Business Highlights

Tue, 04 Aug 2026 08:30:00 -0400

Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5%
Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growth
First half revenue of $54.4M, +44% year-over-year growth; IFRS gross margin of 75.8%
Second quarter IFRS and non-IFRS net income of $2.5M and $3.0M (or $3.8M exc. one-time expenses), versus IFRS and non-IFRS net income of $1.5M and $2.2M in the prior year period
Generated $3.6M in cash in the second quarter
Approximately 3,100 Sofwave systems sold to date and more than 975,000 Sofwave treatments administered since commercialization

Sofwave Medical Reports Second Quarter and First Half 2026 Financial Results and Business Highlights

Tue, 04 Aug 2026 08:30:00 -0400

Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5%
Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growth
First half revenue of $54.4M, +44% year-over-year growth; IFRS gross margin of 75.8%
Second quarter IFRS and non-IFRS net income of $2.5M and $3.0M (or $3.8M exc. one-time expenses), versus IFRS and non-IFRS net income of $1.5M and $2.2M in the prior year period
Generated $3.6M in cash in the second quarter
Approximately 3,100 Sofwave systems sold to date and more than 975,000 Sofwave treatments administered since commercialization

Sofwave to Participate in 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Mon, 27 Jul 2026 08:00:00 -0400

SAN CLEMENTE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 10 – 11, 2026.

About Sofwave Medical
Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines

Sofwave to Participate in 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Mon, 27 Jul 2026 08:00:00 -0400

Sofwave to Participate in 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Mon, 27 Jul 2026 08:00:00 -0400

Sofwave to Participate in 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Mon, 27 Jul 2026 08:00:00 -0400

Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights